NCMP-05. RITUXIMAB AS INITIAL THERAPY FOR THE REVERSAL OF MYASTHENIA GRAVIS NEUROTOXICITY CAUSED BY IPILIMUMAB/NIVOLUMAB

BACKGROUND: In patients with melanoma treated with immune checkpoint inhibitors (ICIs), neurological toxicities developed in 1% treated with Ipilimumab and 3% after Nivolumab. This rises to 14% when co-administered. Patients treated with ICIs are susceptible to Myasthenia Gravis like syndrome. There...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Verma, Neha, Jaffer, Muhammed, Peguero, Edwin, Mokhtari, Sepideh
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2018
Konular:
Abstracts
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216679/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.806
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller